Cellular senescence in cancer treatment: Friend or foe?

Journal of Clinical Investigation

Volumn 113, Issue 2, 2004, Pages 169-174

  Kahlem, Pascal ^a   Dörken, Bernd ^a,b   Schmitt, Clemens A ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CELL DNA; CYCLIN DEPENDENT KINASE 4; PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; DNA; PROTEIN P16INK4A;

APOPTOSIS; CANCER; CANCER REGRESSION; CELL AGING; DNA DAMAGE; DRUG SAFETY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA; DNA DAMAGE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85047694328     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI20784     Document Type: Review

References (55)

1. Schmitt, C.A., et al. 2002. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 109:335-346.
2. te Poele, R.H., Okorokov, A.L., Jardine, L., Cummings, J., and Joel, S.P. 2002. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62:1876-1883.
3. Roninson, I.B., Broude, E.V., and Chang, B.D. 2001. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. 4:303-313.
4. Robles, S.J., and Adami, G.R. 1998. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene. 16:1113-1123.
5. Chang, B.D., et al. 1999. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59:3761-3767.
6. Suzuki, K., et al. 2001. Radiation-induced senescence-like growth arrest requires TP53 function but not telomere shortening. Radiat. Res. 155:248-253.
7. Hayflick, L., and Moorhead, P.S. 1961. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25:585-621.
8. Dimri, G.P., et al. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U. S. A. 92:9363-9367.
9. Campisi, J., Dimri, G., and Hara, E. 1996. Control of replicative senescence. In Handbook of the biology of aging. S.A.J. Rowe, editor. Academic Press. New York, New York, USA. 121-149.
10. Shelton, D.N., Chang, E., Whittier, P.S., Choi, D., and Funk, W.D. 1999. Microarray analysis of replicative senescence. Curr. Biol. 9:939-945.
11. Serrano, M. 1997. The tumor suppressor protein p16INK4a. Exp. Cell Res. 237:7-13.
12. Narita, M., et al. 2003. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 113:703-716.
13. Canman, C.E., and Lim, D.S. 1998. The role of ATM in DNA damage responses and cancer. Oncogene. 17:3301-3308.
14. Tee, A.R., and Proud, C.G. 2000. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene. 19:3021-3031.
15. Abraham, R.T. 2001. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15:2177-2196.
16. Durocher, D., and Jackson, S.P. 2001. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr. Opin. Cell Biol. 13:225-231.
17. Rouse, J., and Jackson, S.P. 2002. Interfaces between the detection, signaling, and repair of DNA damage. Science. 297:547-551.
18. Dent, P., Yacoub, A., Fisher, P.B., Hagan, M.P., and Grant, S. 2003. MAPK pathways in radiation responses. Oncogene. 22:5885-5896.
19. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
20. Sakaguchi, K., et al. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831-2841.
21. Chehab, N.H., Malikzay, A., Stavridi, E.S., and Halazonetis, T.D. 1999. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 96:13777-13782.
22. Shieh, S.Y., Taya, Y., and Prives, C. 1999. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMB0 J. 18:1815-1823.
23. Chao, C., Saito, S., Anderson, C.W., Appella, E., and Xu, Y. 2000. Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 97:11936-11941.
24. Vousden, K.H., and Lu, X. 2002. Live or let die: the cell's response to p53. Nat. Rev. Cancer. 2:594-604.
25. Oda, K., et al. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 102:849-862.
26. D'Orazi, G., et al. 2002. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4:11-19.
27. Webley, K., et al. 2000. Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol. Cell. Biol. 20:2803-2808.
28. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:593-602.
29. Shapiro, G.I., Edwards, C.D., Ewen, M.E., and Rollins, B.J. 1998. p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol. Cell. Biol. 18:378-387.
30. Agami, R., and Bernards, R. 2000. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 102:55-66.
31. Seidita, G., Polizzi, D., Costanzo, G., Costa, S., and Di Leonardo, A. 2000. Differential gene expression in p53-mediated G(1) arrest of human fibroblasts after gamma-irradiation or N-phosphoacetyl-L-aspartate treatment. Carcinogenesis. 21:2203-2210.
32. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A., and Jacks, T. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:847-849.
33. Schmitt, C.A., Wallace-Brodeur, R.R., Rosenthal, C.T., McCurrach, M.E., and Lowe, S.W. 2000. DNA damage responses and chemosensitivity in the E mu-myc mouse lymphoma model. Cold Spring Harb. Symp. Quant. Biol. 65:499-510.
34. Lee, S., and Schmitt, C.A. 2003. Chemotherapy response and resistance. Curr. Opin. Genet. Dev. 13:90-96.
35. Brookes, S., et al. 2002. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J. 21:2936-2945.
36. Wang, E. 1995. Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res. 55:2284-2292.
37. Hansen, M.H., Nielsen, H., and Ditzel, H.J. 2001. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc. Natl. Acad. Sci. U. S. A. 98:12659-12664.
38. Lauber, K., et al. 2003. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell. 113:717-730.
39. Savill, J.S., et al. 1989. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J. Clin. Invest. 83:865-875.
40. Murphy, J.F., McGregor, J.L., and Leung, L.L. 1998. Senescent human neutrophil binding to thrombospondin (TSP): evidence for a TSP-independent pathway of phagocytosis by macrophages. Br. J. Haematol. 102:957-964.
41. Gerland, L.M., et al. 2003. Association of increased autophagic inclusions labeled for beta-galactosidase with fibroblastic aging. Exp. Gerontol. 38:887-895.
42. Waldman, T., et al. 1997. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med. 3:1034-1036.
43. Krtolica, A., Parrinello, S., Lockett, S., Desprez, P.Y., and Campisi, J. 2001. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. U. S. A. 98:12072-12077.
44. Beausejour, C.M., et al. 2003. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22:4212-4222.
45. Dirac, A.M., and Bernards, R. 2003. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J. Biol. Chem. 278:11731-11734.
46. Sage, J., Miller, A.L., Perez-Mancera, P.A., Wysocki, J.M., and Jacks, T. 2003. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. 424:223-228.
47. Alexander, K., Yang, H.S., and Hinds, P.W. 2003. pRb inactivation in senescent cells leads to an E2F-dependent apoptosis requiring p73. Mol. Cancer Res. 1:716-728.
48. Schmitt, C.A., McCurrach, M.E., de Stanchina, E., Wallace-Brodeur, R.R., and Lowe, S.W. 1999. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13:2670-2677.
49. Dohner, H., et al. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343:1910-1916.
50. Schmitt, C.A., Rosenthal, C.T., and Lowe, S.W. 2000. Genetic analysis of chemoresistance in primary murine lymphomas. Nat. Med. 6:1029-1035.
51. Chang, J.C., et al. 2003. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 362:362-369.
52. Holleman, A., Den Boer, M.L., Kazemier, K.M., Janka-Schaub, G.E., and Pieters, R. 2003. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukaemia. Blood. 102:4541-4546.
53. Lodygin, D., Menssen, A., and Hermeking, H. 2002. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J. Clin. Invest. 110:1717-1727. doi:10.1172/ JCI200216588.
54. Soni, R., et al. 2001. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl. Cancer Inst. 93:436-446.
55. Hall, A.H., and Alexander, K.A. 2003. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J. Virol. 77:6066-6069.